{"id":60131,"date":"2026-03-20T12:39:37","date_gmt":"2026-03-20T04:39:37","guid":{"rendered":"https:\/\/flcube.com\/?p=60131"},"modified":"2026-03-20T12:39:37","modified_gmt":"2026-03-20T04:39:37","slug":"eli-lillys-retatrutide-delivers-2-0-a1c-reduction-and-36-6-lbs-weight-loss-in-phase-3-diabetes-trial-triple-agonist-shows-best-in-class-efficacy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60131","title":{"rendered":"Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial \u2013 Triple\u2011Agonist Shows Best\u2011in\u2011Class Efficacy"},"content":{"rendered":"\n

Eli Lilly and Company<\/strong> (NYSE: LLY<\/a>) announced positive topline results<\/strong> from the Phase 3 TRANSCEND\u2011T2D\u20111 trial<\/strong>, demonstrating that retatrutide<\/strong> \u2013 a first\u2011in\u2011class once\u2011weekly GIP\/GLP\u20111\/glucagon triple hormone receptor agonist<\/strong> \u2013 achieved superior A1C reduction of up to 2.0%<\/strong> and weight loss of up to 36.6 lbs (16.8%)<\/strong> at 40 weeks in adults with type 2 diabetes<\/strong>, positioning the investigational therapy as a potential best\u2011in\u2011class<\/strong> metabolic disease treatment.<\/p>\n\n\n\n

Clinical Milestone \u2013 TRANSCEND\u2011T2D\u20111 Phase 3<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Study<\/strong><\/td>TRANSCEND\u2011T2D\u20111 (Phase 3)<\/td><\/tr>
Molecule<\/strong><\/td>Retatrutide \u2013 first\u2011in\u2011class triple agonist<\/strong> (GIP + GLP\u20111 + glucagon receptors)<\/td><\/tr>
Patient Population<\/strong><\/td>Adults with type 2 diabetes, inadequate glycemic control with diet\/exercise alone<\/td><\/tr>
Mean Diabetes Duration<\/strong><\/td>2.5 years<\/td><\/tr>
Dosing<\/strong><\/td>Once\u2011weekly injection<\/td><\/tr>
Primary Endpoint<\/strong><\/td>A1C reduction vs. placebo<\/td><\/tr>
Key Secondary Endpoint<\/strong><\/td>Weight loss vs. placebo<\/td><\/tr>
Analysis Methods<\/strong><\/td>Efficacy estimand + treatment\u2011regimen estimand<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Efficacy Results \u2013 40\u2011Week Data<\/h2>\n\n\n\n
Endpoint<\/th>Retatrutide Result<\/th>Clinical Significance<\/th><\/tr><\/thead>
A1C Reduction (Primary)<\/strong><\/td>Up to 2.0%<\/strong> (efficacy estimand)<\/td>Near\u2011normalization of glycemic control; exceeds semaglutide (1.8%) and tirzepatide (2.0\u20112.3%) benchmarks<\/td><\/tr>
Weight Loss (Key Secondary)<\/strong><\/td>Up to 36.6 lbs (16.8%)<\/strong> (efficacy estimand)<\/td>Best\u2011in\u2011class metabolic efficacy; weight loss trajectory continued through treatment period<\/td><\/tr>
Dose Response<\/strong><\/td>4 mg, 9 mg, 12 mg dose\u2011dependent efficacy<\/td>Clear dose\u2011optimization pathway for personalized therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Safety Profile<\/h2>\n\n\n\n
Parameter<\/th>Retatrutide 4 mg<\/th>Retatrutide 9 mg<\/th>Retatrutide 12 mg<\/th>Placebo<\/th><\/tr><\/thead>
Discontinuation Due to Adverse Events<\/strong><\/td>2.2%<\/td>4.5%<\/td>5.1%<\/td>0.0%<\/td><\/tr>
Overall Safety<\/strong><\/td>Consistent with incretin\u2011based therapies<\/td>\u2013<\/td>\u2013<\/td>\u2013<\/td><\/tr>
New Safety Signals<\/strong><\/td>None identified<\/td>\u2013<\/td>\u2013<\/td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n